
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is a clinical-stage biopharmaceutical company with a promising suite of therapeutic platforms and a diversified pipeline in oncology and other therapeutic areas, including its HER2-targeted bispecific antibody zanidatamab. With a total firm value of $3.8B and a number of ongoing clinical trials, including the recently FDA-approved zanidatamab in 1L GEA, Zymeworks is poised for potential long-term success. However, risks such as clinical trial failures, competition, regulatory uncertainty, and industry trends should be considered when evaluating this investment opportunity.
Bears say
Zymeworks is facing multiple challenges as a clinical-stage biopharmaceutical company, including lower than estimated revenues and higher than anticipated expenses. The recent acquisitions have resulted in the impairment of acquired IPR&D, and the company heavily relies on partnerships for commercial success, increasing its marketing risk. Furthermore, the company's sole asset YUPELRI faces competition and potential generic entrants, and its pipeline products are not yet approved by any regulatory body, posing regulatory risks. The company has low cash flow and limited pipeline optionality, leading to financial risk and a potential sale.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares